Novo Nordisk's anti-TFPI antibody concizumab has ... including Japan, Australia, and Switzerland, but was rejected by the FDA last year with a request for more information related to the ...

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

Novo Nordisk’s bid to provide a once-weekly ... Australia, Japan, and Switzerland under the Awiqli brand name, as well as in China. Eli Lilly is its nearest rival, developing a once-weekly ...

The spiraling consequences underline the real-world harms from Donald Trump's upending of decades-old U.S. initiatives.

That’s the conclusion of hiring managers at four of the state’s leading life sciences companies who spoke at a recent career ...

That included pharmaceutical firm Novo Nordisk, semiconductor manufacturer ... but weak performance helped stocks from France and Switzerland make up ground. Those countries weigh between 15% ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...